Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT02393859 · COMPLETED

Trial details

NCT number: NCT02393859
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Leukemia, Acute Lymphoblastic

Start date: 2015-11-10
Primary completion: 2019-07-17
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.